Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor

被引:2
|
作者
Vonk, Steffie E. M. [1 ]
Altenburg, Josje [2 ]
Mathot, Ron A. A. [1 ]
Kemper, E. Marleen [1 ,3 ]
机构
[1] Univ Amsterdam, Dept Hosp Pharm & Clin Pharmacol, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Dept Pulm Med, Amsterdam UMC, Meibergdreef 9, Amsterdam, Netherlands
[3] Univ Amsterdam, Dept Vasc Med, Amsterdam UMC, Amsterdam, Netherlands
关键词
Elexacaftor-tezacaftor-ivacaftor; Therapeutic drug monitoring; Area under the curve; Trough concentration; CFTR modulators;
D O I
10.1016/j.jcf.2024.03.010
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Therapeutic drug monitoring (TDM) of elexacaftor, tezacaftor, ivacaftor (ETI) could be a useful tool to increase efficacy and decrease the risk of adverse effects in people with Cystic Fibrosis (pwCF). It is however unclear whether drug exposure should be monitored by assessment of trough (C-min) levels or determination of the area under the curve (AUC). Hence, in this study the correlation between measured C min concentration and AUC was evaluated. Serial plasma samples, including C-min , were drawn after administration of ETI in order to calculate the AUC and assess the correlation between the two parameters. A linear correlation between C- min and AUC 0-24h was found, with Pearson's r correlation coefficients of 0.963, 0.908 and 0.860 for elexacaftor, tezacaftor and ivacaftor, respectively. Exposure of ETI may be monitored by assessment of C( min )levels.
引用
收藏
页码:1007 / 1009
页数:3
相关论文
共 50 条
  • [21] Efficacy of elexacaftor/tezacaftor/ivacaftor therapy assessed by lung ultrasound
    Krivec, U.
    Praprotnik, M.
    Aldeco, M.
    Lepej, D.
    Zver, A.
    Berlot, J. Rodman
    Smid, S. Setina
    Dolenc, S.
    Krivec, J. Lozar
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [22] Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events
    Ramsey, Bonnie
    Correll, Christoph U.
    DeMaso, David R.
    McKone, Edward
    Tullis, Elizabeth
    Taylor-Cousar, Jennifer L.
    Chu, Chenghao
    Volkova, Nataliya
    Ahluwalia, Neil
    Waltz, David
    Tian, Simon
    Mall, Marcus A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209 (03) : 299 - 306
  • [23] Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis
    Nichols, David P.
    Paynter, Alex C.
    Heltshe, Sonya L.
    Donaldson, Scott H.
    Frederick, Carla A.
    Freedman, Steven D.
    Gelfond, Daniel
    Hoffman, Lucas R.
    Kelly, Andrea
    Narkewicz, Michael R.
    Pittman, Jessica E.
    Ratjen, Felix
    Rosenfeld, Margaret
    Sagel, Scott D.
    Schwarzenberg, Sarah Jane
    Singh, Pradeep K.
    Solomon, George M.
    Stalvey, Michael S.
    Clancy, John P.
    Kirby, Shannon
    Van Dalfsen, Jill M.
    Kloster, Margaret H.
    Rowe, Steven M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205 (05) : 529 - 539
  • [24] Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant
    Young, Dave
    Bartlett, Lauren E.
    Guimbellot, Jennifer
    Milinic, Tijana
    Burdis, Nora
    Gill, Eliana R.
    Lease, Erika D.
    Goss, Christopher H.
    Kapnadak, Siddhartha G.
    Ramos, Kathleen J.
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (03) : 545 - 548
  • [25] Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor
    Sanders, Don B.
    Mayer-Hamblett, Nicole
    Rosenfeld, Margaret
    Polinieni, Deepika
    Dasenbrook, Elliott
    Szczesniak, Rhonda
    Cromwell, Elizabeth A.
    JOURNAL OF CYSTIC FIBROSIS, 2025, 24 (02) : 255 - 262
  • [26] Elexacaftor/Ivacaftor/Tezacaftor in Lung Transplant Recipients: A Case Series
    Potter, L. M.
    Vargas, B.
    Rotolo, S. M.
    McEwen, C. Q.
    Tsui, K.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S375 - S375
  • [27] Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
    Miller, Matthew J.
    Foroozan, Rod
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2022, 57 (01): : E6 - E10
  • [28] Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation
    Cheng, Ann
    Baker, Olivia
    Hill, Uta
    BMJ CASE REPORTS, 2022, 15 (03)
  • [29] Heterogeneity in response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
    Alicandro, Gianfranco
    Gramegna, Andrea
    Bellino, Federica
    Sciarrabba, Sathya Calogero
    Lanfranchi, Chiara
    Contarini, Martina
    Retucci, Mariangela
    Blasi, Francesco
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (06) : 1072 - 1079